Decitabine

Lung Neoplasms

Small moleculePhase 1Dormant

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 73/ 100

Competitive context

52 Active assets in the Lung Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Carboplatin Nanfang Hospital, Southern Medical University	Phase 4	BB
BELAGENPUMATUCEL-L (SK-LU-1) NovaRx Corporation	Phase 3	BB
Nivolumab Hospital Israelita Albert Einstein	Phase 2	BB
Icotinib Fuda Cancer Hospital, Guangzhou	Phase 4	BB
Rivoceranib Fuzhou General Hospital	Phase 3	BB

View all 50 →

Same molecule, other indications

Decitabine is also rated in:

disease related to hematopoietic stem cell transplantDormant

BBB

Indicative ·

72 / 100

acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant

BB

Indicative ·

70 / 100

acute myeloid leukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.